A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yangbing, Zhang, Zehui, Zou, Siyi, Li, Fanlu, Chen, Hao, Peng, Chenghong, Deng, Xiaxing, Wen, Chenlei, Shen, Baiyong, Zhan, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010262/
https://www.ncbi.nlm.nih.gov/pubmed/33816276
http://dx.doi.org/10.3389/fonc.2021.634881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010262/
https://www.ncbi.nlm.nih.gov/pubmed/33816276
http://dx.doi.org/10.3389/fonc.2021.634881

Ejemplares similares